Strattera 25 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

strattera 25 mg kapseli, kova

eli lilly finland oy ab - atomoxetine hydrochloride - kapseli, kova - 25 mg - atomoksetiini

Strattera 40 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

strattera 40 mg kapseli, kova

eli lilly finland oy ab - atomoxetine hydrochloride - kapseli, kova - 40 mg - atomoksetiini

Strattera 60 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

strattera 60 mg kapseli, kova

eli lilly finland oy ab - atomoxetine hydrochloride - kapseli, kova - 60 mg - atomoksetiini

Strattera 80 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

strattera 80 mg kapseli, kova

eli lilly finland oy ab - atomoxetine hydrochloride - kapseli, kova - 80 mg - atomoksetiini

Strattera 100 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

strattera 100 mg kapseli, kova

eli lilly finland oy ab - atomoxetine hydrochloride - kapseli, kova - 100 mg - atomoksetiini

STRATTERA 4 mg/ml oraaliliuos Suomi - suomi - Fimea (Suomen lääkevirasto)

strattera 4 mg/ml oraaliliuos

eli lilly finland oy ab - atomoxetini hydrochloridum - oraaliliuos - 4 mg/ml - atomoksetiini

Verzenios Euroopan unioni - suomi - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - rintojen kasvaimet - antineoplastiset aineet - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Retsevmo Euroopan unioni - suomi - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiset aineet - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Jaypirca Euroopan unioni - suomi - EMA (European Medicines Agency)

jaypirca

eli lilly nederland b.v. - pirtobrutinib - lymfooma, mantle-cell - proteiinikinaasin estäjät - treatment of mantle cell lymphoma (mcl).

Abasaglar (previously Abasria) Euroopan unioni - suomi - EMA (European Medicines Agency)

abasaglar (previously abasria)

eli lilly nederland b.v. - glargininsuliini - diabetes mellitus - diabeetilla käytettävät lääkkeet - diabetes mellituksen hoito aikuisilla, nuorilla ja yli 2-vuotiailla lapsilla.